Background: One bottleneck for adoptive T cell therapy (ACT) is recruitment of T cells into tumors. We hypothesized that combining tumor-specific T cells, modified with a marker antigen and a bispecific antibody (BiAb) that selectively recognizes transduced T cells and tumor cells would improve T cell recruitment to tumors and enhance therapeutic efficacy.
Tumor antigen-specific T cells are attractive tools for cancer therapy, because they are highly specific (1) , can actively infiltrate tumor tissue where their target antigen is expressed (2) , and are capable of serial-target cell killing (3) . However, efficacy of T cell therapy against solid tumors without host conditioning is limited, and this treatment only leads to responses in a small subset of patients (two out of 11) (4) .
Host conditioning with total body irradiation or T celldepleting chemotherapy has been investigated to improve the therapeutic efficacy of adoptive T cell therapy (ACT) (5) . However, these treatments are accompanied by frequent high-grade (3 or 4) toxicities, limiting their use to restricted patient populations (6) . Thus, there is a need for strategies addressing the inherent limitations of ACT without causing severe side effects.
Bispecific antibodies (BiAbs) with specificity against a tumor-associated antigen and against a T cell marker are currently in clinical development to recruit T cells to cancer cells (7, 8) . Most T cell-recruiting BiAb address T cells by the pan-T cell marker CD3. They have proven their efficacy in clinical phase II (7) and III trials (9) . The combination of ACT with BiAb application is an attractive strategy to enhance the efficacy of either approach alone, but so far have yielded disappointing results because of the induction of a cytokine storm upon T cell activation (10) .
Because of the ability of BiAbs to link T cells with tumor cells, we hypothesized that a nonsignaling (inert) antigen introduced into the tumor-reactive T cell could be used as the target for one binding arm of a BiAb (Figure 1 ). In contrast to using an anti-CD3 BiAb, T cell activation in this setting can only result from T cell receptor (TCR) engagement. Thus T cell degranulation can only occur at the tumor site and not systemically in other organs or in the circulation. Combining ACT of tumor-specific T cells expressing an inert marker antigen with a cognate BiAb recognizing both the transduced T cell and a tumor antigen has the potential to facilitate tumor-specific T cell engagement in the tumor tissue while avoiding systemic T cell activation by functionally separating the linking of T cells to tumors and T cell activation.
Methods

Animal Experiments
Wild-type C57BL/6RJ mice were purchased from Janvier (St. Berthevin, France). Mice transgenic for a T cell receptor specific for the immunodominant epitope I of the simian virus 40 (SV40) T antigen (TCR-I) were purchased from the Jackson Laboratory (stock number 005236). mGC8 tumors were induced subcutaneously with 3 x 10 6 cells. Prior to treatment, mice were randomized to the treatment groups (n = six to 12 per group), and tumors were measured every other day in a nonblinded fashion. Tumor volume was estimated using the following formula: V = 4/3 x π x L 1 2 x L 2 (with L 1 defined as maximal diameter and L 2 , the diameter perpendicular to L 1 ). T cells and antibodies were given intravenous (i.v.). All animal studies were approved by the local regulatory agency (Regierung von Oberbayern). Power calculations were done prior to study approval.
T Cell Transduction
Truncated human epithelial growth factor receptor (referred to as ΔEGFR), comprising amino acids 1-667, was cloned into the retroviral vector pMP71 (kindly provided by C. Baum, Hannover, Germany) and into the retroviral bicistronic pBULLET vector containing BW431/26-scFv-Fc-CD28-CD3 CAR specific for CEA (11) . pMP71-ΔEGFR was used for transduction of human and murine wild-type T cells, the murine T cell line B3Z, the human tyrosinase specific T cell clone IVSB and the human T cell line Jurkat. For human CEA-CAR T cell transduction, the pBULLET vector was used. Transduction protocols have been described in detail (11) (12) (13) . In brief, Plat-E cells were transfected and the produced retrovirus was used to transduce murine T cells prestimulated by anti-CD3 and anti-CD28 antibodies (eBioscience, Frankfurt, Germany, clones 145-2C11 and 37.51, respectively) and IL-2 (10 IU/mL). In subsequent cultures, anti-CD3, anti-CD28 beads (Life Technologies, Carlsbad, CA), and IL-15 (50 ng/ mL, Peprotech, Hamburg, Germany) were applied. For human T cell transduction, 293T cells were transfected with the respective retroviral vector together with the plasmids pcDNA3.1-MLVg/p and pALF10A1 (both kindly provided by W. Uckert, Max Delbruck Centre, Berlin). Retrovirus was used to transduce 
Interferon-γ Release Assay
ΔEGFR-transduced IVSB T cell clone and ΔEGFR-carcinoembryonic antigen (CEA)-chimeric antigen receptor (CAR)-transduced T cells were cocultivated with mel624.38 and MelA375 or LS174T for 48 hours at a ratio of 10:1 or 1:2.5, respectively. IFN-γ release was quantified by enzyme-linked immunosorbent assay (ELISA; R & D). For IVSB T cell clone experiments, the coculture was preceded by cell adhesion of transduced and untransduced T cells using anti-EGFR antibody AY13 (Biolegend, London, UK) labeled with APC and anti-APC magnetic cell sorting (Miltenyi, Bergisch-Gladbach, Germany); retained cells were used for the assay. For CEA-CAR experiments, T cells were preloaded with ER-Met BiAb for 30 minutes prior to coculture.
Statistical Analysis
For statistics, GraphPad Prism software version 5.0b was used. All variables reported are continuous. For in vitro analysis, differences between experimental conditions were analyzed using the unpaired two-sided Student's t test; P values under .05 were considered statistically significant. For in vivo data, differences between groups were analyzed using two-way analysis of variance (ANOVA) with correction for multiple testing by the Bonferroni method. For tumor growth analysis, D'Agostino Pearson omnibus normality analysis was performed on 21 tumor-bearing but untreated mice (620 ± 619 mm 2 , P = .021); thus, normality of tumor growth distribution was assumed. Overall survival was analyzed by log-rank test. Survival is defined in days from tumor induction until natural death or until mice were killed because one of the following criteria was reached: tumor size greater than 225 mm 2 , weight loss greater than 15% or prolonged distress, as defined by the German Society for Laboratory Animal Science. Data are shown as mean values of a minimum of three biological replicates or independent experiments ± standard deviation.
Results
Murine EpCAM and Human EGFR as Model Targets in a Syngeneic Murine Tumor Model
To test our hypothesis of enhancing T cell to tumor binding by BiAbs, we used mGC8 gastric cancer cells as target cells or for inducing subcutaneous tumors. mGC8 cells are positive for murine EpCAM on the cell surface (Supplementary Figure 1A , available online) and present the immunodominant epitope of the SV40 T antigen in the context of H-2 Kd (14) . To assess whether EpCAM would be amenable to antibody-based therapy, we injected tumor-bearing mice with the monoclonal rat anti-EpCAM antibody G8.8. Deposition of this antibody was detected by direct immunofluorescence in the tumor and in all organs found positive for EpCAM by expression analysis (Supplementary Figure 1 , B and C). Human EGFR was used because of lack of cross-reactivity of the anti-EGFR antibody cetuximab (Mab225) with murine tissue (15) . Thus, Mab225 did not detect the cell line mGC8 and did not react to any of the tested organs (tumor, spleen, liver, lung, kidney, and bowel, data not shown).
Generation of a Novel Anti-EGFR x Anti-EpCAM (ER-Ep) BiAb
We generated a novel BiAb-binding EGFR and murine EpCAM ectodomains with similar affinity as compared with the monoclonal parental antibodies ( Figure 1 and Table 1 ). The ER-Ep BiAb is not cross-reactive to murine EGFR and thus does not bind to the cell line mGC8 used in this study. Surface plasmon resonance analysis confirmed that the BiAb was able to bind both antigens simultaneously (Table 1 ; Supplementary Figure 2A , available online). The ER-Ep BiAb did not induce statistically significant antibody-dependent cellular cytotoxicity or complement dependent cytotoxicity (data not shown).
Cross-Linking of ΔEGFR + T Cells With EpCAM + Tumor Cells and Directed Killing of Tumor Cells
The ΔEGFR construct was used to stably transduce T cells (for representative transduction result see Supplementary Figure 2B , available online). The ability of the ER-Ep BiAb to bring ΔEGFR-transduced T cells and EpCAM + tumor cells into physical proximity was addressed in vitro. The ER-Ep BiAb retained more ΔEGFR + T cells in proximity to the tumor cells compared with control ER-Dig BiAb, which binds only to EGFR (mean retention ± SD 87 % ± 13 % vs 24% ± 8 %, P = .002) and to incubation without antibody (87 % ± 13 % vs 9 ± 3 %, P < .001) (Figures 2, A, B , and C). Remarkably, this ability to link T cells to tumor cells resulted in lysis of the target cells, with a maximal lysis at a E:T ratio of 10:1 (TCR-I + ER-Ep BiAb + mGC8 vs TCR-I + ER-Dig BiAb + mGC8, 83 ± 12 % vs -18.5 ± 1%, P < .001) ( Figure 2D ). Lysis was dependent on the simultaneous presence of the four interacting components: ΔEGFR and TCR-I targeting SV40 T antigen on the T cells; EpCAM and SV40 T antigen on the tumor cells ( Figure 2D ; Supplementary Table 1 for P values, available online). , P = .004 at day 44) ( Figure 3A) . The in vivo efficacy of the combined T cell and BiAb treatment was confirmed in a second in vivo study by treatment of mice with the ER-Ep BiAb alone, as well as with two different doses of the ER-Ep BiAb together with ACT ( Figure 3B ). The ER-Ep BiAb alone did not confer therapeutic efficacy, whereas ER-Ep BiAb together with ACT showed a dose-dependent effect with 10 mg/kg of BiAb being more effective than 2 mg/kg (10 ± 7 mm 3 vs 205 ± 83 mm 3 , P = .038 at day 54) (see supplementary Table 3 , available online, for a summary of P values; Figure 3B ). Both low and high doses of ER-Ep BiAb plus ACT prolonged survival of tumor-bearing mice compared with ACT with a murinized monospecific anti-EpCAM antibody (median survival high dose BiAb 95 vs control 75 days, P < .001) ( Figure 3C ). Mice tolerated the treatment well with no obvious signs of toxicity. In addition, non-tumor-bearing animals treated with the combination regimen showed no diarrhea or weight loss (data not shown) during an observation period of 100 days. In line with these results, no increase in T cell infiltration was found in organs lacking the SV40 T antigen (Supplementary Figure 3A , available online).
Impact of ER-Ep BiAb and ΔEGFR + TCR Transgenic T Cells on mGC8 Tumor Growth
Influence of the Combination Therapy on T Cell Infiltration Into the Tumor
To investigate the mechanisms contributing to tumor control or to escape from therapy, we analyzed by immunohistochemistry the tumors depicted in Figures 3, A and B , for the presence of infiltrating T cells (from mice which had to be killed because of a prespecified tumor-size threshold). Tumors from mice treated with ER-Ep BiAb plus ΔEGFR-transduced T cells contained more CD3 + T cells than the group treated with ΔEGFR-transduced T cells without BiAb (0.40 ± 0.42 vs 0.09 ± 0.14 per high power field, P = .021) (Supplementary Figure 3 , B-D, available online).
Bispecific Antibody Enhances Recognition of Tumor Cells by TCR-and CAR-Transduced Human T Cells
To test if our strategy can also be applied to target human tumors, we used the previously described EGFR x c-Met bispecific antibody (ER-Met BiAb) (16) together with either ΔEGFR-transduced human T cells, the HLA-A2-tyrosinase-specific human T cell clone IVSB (17) or human CEA-CAR-specific T cells ( Figure 4A) (11) . We chose c-Met because of its wide expression on human tumor cells (18) . The ER-Met BiAb retained ΔEGFR + T cells to immobilized c-Met (57 ± 12 % vs 7 ± 2 %, P = .002) (Figure 4B ), without affecting ΔEGFR -T cells (6 ± 2 % vs 5 ± 0.4 %, P = .280). Remarkably, retention of ΔEGFR-transduced tyrosinase-specific IVSB T cells strongly enhanced recognition of the tyrosinase + HLA-A2 + mel624 melanoma cells but not of the tyrosinase -HLA-A2 + melA375 melanoma cells, as measured by IFN-γ release by the T cells (877 ± 63 ng/mL vs 166 ± 27 ng/mL, P < .001) ( Figure 4C ). Similarly, coculture of ΔEGFR-and CEA-CAR-transduced T cells with CEA + LS174T colon cancer cells in the presence of ER-Met BiAb increased CAR-mediated T cell activation indicated by antigen-specific IFN-γ release; the effect was most prominent when using suboptimal numbers of anti-CEA-CAR T cells (IFN-γ release 330 ± 39 ng/mL vs 0 ± 0 ng/mL, P = .001) ( Figure 4D ). Thus, the ER-Met BiAb is able to enhance the TCR-or CAR-mediated activation of T cells by targeting T cells to tumor cells.
Discussion
Our study shows that, in mice, treatment with ER-Ep BiAb in conjunction with ACT of marker antigen-transduced tumor-specific T cells resulted in enhanced T cell-mediated tumor killing and in T cell accumulation in subcutaneous mGC8 tumors. This novel treatment approach also enhanced tumor recognition by human T cells via a tumor-specific TCR or CAR, suggesting the amenability of the strategy against human tumors. This is the first report demonstrating that a nonactivating BiAb is able to specifically accumulate tumor-specific T cells in the tumor without the need of polyclonal T cell activation. The strategy has the potential to enhance safety of ACT by avoiding triggering of T cells of other specificities at sites distant to the tumor.
The principal amenability of targeting EpCAM + murine and human tumors for recruitment and activation of T cells has previously been shown (19) . This provided the basis for selecting EpCAM as a model antigen for BiAb therapy. Similarly, we used c-Met as a BiAb target because of its broad expression in human malignancies and because of the already proven employability of a c-Met-bispecific antibody (16, 18) . A challenge in translating the combined ACT plus BiAb strategy into clinical application is the choice of an appropriate marker antigen for human T cell modification. Because ΔEGFR, as employed in the present study, has been described to be of low spontaneous immunogenicity (20), we selected it as a suitable human target in both murine and human tumor models. Given the favorable safety profile of EGFR-targeted antibody therapy, EGFR may be a suitable antigen for clinical application. In fact, ΔEGFR-transduced T cells are currently used as a safety switch in an adoptive T cell trial (NCT01815749) to permit T cell depletion through EGFR-targeted antibodies if required. However, the ubiquitous EGFR expression and thus the targeting of T * Ka = association constant; t ½ = half life; EGFR = epithelial growth factor receptor; EpCAM = epithelial cell adhesion molecule; ER-Ep Biab = anti-EGFR x anti-EpCAM bispecific antibody; kd = dissociation constant; KD = dissociation equilibrium constant. cells to nontumor tissue may limit therapeutic benefit. Other T cell marker proteins will be needed to be explored before clinical testing, such as EGFR variant 3, which is a tumor-specific mutation in EGFR, targetable by antibodies and found only in certain tumor entities such as glioblastoma (21) . The choice of tumor antigen specificity for the BiAb design is also challenging, because most tumor-associated antigens are not tumor specific (22) . In the absence of ideal targets, both the TCR of the adoptively transferred T cells and the BiAb-targeted tumor antigen should be selected on the basis of a restricted expression pattern. However, even targeting less abundant antigens may result in severe side effects (23) . In our strategy, the absence of an activating component in the BiAb design, such as a CD3 binding domain, and the specificity of the T cells for a distinct tumor antigen presented in the context of major histocompatibility complex (MHC) class I are likely to enhance therapeutic safety. Avoiding unwanted, undirected T cell activation remains a major challenge with respect to the T cell recruiting BiAb.
Previous clinical studies have used BiAb to recruit T cells to tumor cells in patients (10, 24, 25) . A major difference to our study is that all previous approaches used the activating 
